+33(0)1 42 54 60 64 | contact@welcomeurope.com

EU4Health – Action grants for the Computer-aided Drug Repurposing for Cancer Therapy Project – 2021

The EU4Health Programme aims at improving human health throughout the Union and ensuring a high level of protection of human health in all Union policies and activities.

2022-01-25
3 million euro
Close

Appeal framework

Institution European Commission
Sectors Health
Beneficiaries
Regions European Economic Area, European Union
Details
  • Countries associated to the EU4Health Programme;
  • Countries which are in ongoing negotiations for an association agreement and where the agreement enters into force before grant signature.

Content reserved for subscribers

Register for free to access the content

Free access to all information

Priorities and funded actions

Objective

  • To identify potential viable effective anti-cancer drugs by making use and piloting ‘in-silico drug repurposing’.

Priority

  • Priority 1 : Launching of an EU platform based on ‘computational drug networks’ to predict, in-silico, the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease biomarkers.
  • Priority 2 : Start with cancers with poor prognosis and rare cancers, and using high-performance computing

Among financed actions

  • Launch an EU platform based on ‘computational drug networks’
  • Development of a concept for drug re-purposing in the field of cancer care with focus on innovative computer aided approaches;
  • Proof of concept and piloting of the approach;
  • Devise and test models for closer collaboration among stakeholders;
  • Concept for the sustainable establishment of an EU platform and recommendations for further development work.

Additional information

  • This call for proposals is an open call for proposals.
  • Initial duration of the action: 36 months.

Eligibility

  • Be a legal entity (public or private);
  • Be established in one of the eligible countries.
Financement
  • Amount of the grant: 3 million euro;
  • Co-financing rate: up to 80% of the total eligible costs.

Test your eligibility

Need help with your public financing ?

Similar news

27 July 2018

40 million euro for cancer treatment research

Lire l'aticle

10 February 2021

A 4 billion euro plan to fight against cancer

Lire l'aticle